Based on such evidence, beneficial effects of anti-estrogen therapy (e.g. with tamoxifen) in ER + BC patients may include also increased protein levels and activity of COMT, however, this assumption requires further confirmation and evaluation, also because the knowledge on ER binding to COMT promoter remains unclear71–73. The gene discussed is ESR1; the disease is breast cancer.